2017 was a milestone year for the immuno-oncology industry. There was big headline news; Novartis’ Kymriah and Kite’s submission of their ZUMA-1 trial to European regulators, as well as numerous incremental wins. For example, the success of a range of combinations that produced better-than-expected patient response rates in NSCLC patients. With these successes, I can’t help but wonder what the next 12 months will bring…
One thing is for sure, improving patient response rates is at the top of the priority list for the whole community.
This e-book explores the importance and challenges of improving patient response. It also provides in-depth analysis, insight and knowledge from the industry, including:
- Developments in combination therapies and the impact on patient response rates
- The use of precision medicine in immuno-oncology
- The impact of trial design on patient response rates and rational trial design vs. empirical science
- Regulatory challenges of immuno-oncology combinations with advanced therapy medicinal products
The common denominator across all of these insights is one of collaboration and partnerships, whether it’s between academia, biotech and big pharma, a sponsor and a vendor or two individuals with a common goal. Without ‘combinations’ and collaborations, we cannot hope to significantly improve patient response rates and, ultimately, improve the lives of patients in need.